The development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion, especially within 30 ...

(American Journal of Gastroenterology) Early hepatic encephalopathy following transjugular intrahepatic portosystemic shunt insertion was associated with worse survival, suggesting the need for ...

DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

Liver shunts in dogs occur when veins that usually carry blood to the liver bypass the organ via an abnormal vessel. They can be tricky to deal with and cause some serious health issues if left ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

Transjugular intrahepatic portosystemic shunt (TIPS) placement alleviates portal hypertension symptoms. Hepatic encephalopathy (HE) is a common complication of TIPS, impacting patient quality of life ...

and finally the availability of transjugular intrahepatic portosystemic stent shunt (TIPSS). These guidelines deal specifically with the management of varices in patients with cirrhosis and are not ...

20,21 Management of portal hypertension ascites in patients with advanced cirrhosis has been significantly improved through the increased adoption of the transjugular intrahepatic portosystemic shunt ...

Learn about the increased pressure in the portal vein, its causes like cirrhosis, and resulting complications such as ...

Ghent, Belgium – 18 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart ...